Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators.

N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.

PMID:
20375404
[PubMed - indexed for MEDLINE]
Free Article
2.

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.

Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J.

Br J Cancer. 2009 Aug 18;101(4):621-7. doi: 10.1038/sj.bjc.6605211.

PMID:
19672264
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

PMID:
19474385
[PubMed - indexed for MEDLINE]
Free Article
4.

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.

André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W.

Br J Cancer. 2008 Sep 16;99(6):862-7. doi: 10.1038/sj.bjc.6604628.

PMID:
19238628
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ.

N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. Erratum in: N Engl J Med. 2010 Dec 23;363(26):2573.

PMID:
19196673
[PubMed - indexed for MEDLINE]
Free Article
6.

A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.

Kim HJ, Lee NS, Lee SC, Bae SB, Kim CK, Cheon YG, Kim YS, Moon JH, Cho YD, Park SH, Lee KT, Park SK, Won JH, Park HS, Hong DS.

Cancer Chemother Pharmacol. 2009 Jul;64(2):371-7. doi: 10.1007/s00280-008-0883-7. Epub 2009 Jan 14.

PMID:
19142638
[PubMed - indexed for MEDLINE]
7.

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J.

J Clin Oncol. 2009 Feb 20;27(6):843-50. doi: 10.1200/JCO.2008.18.3301. Epub 2009 Jan 12. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3263. Lin, Elinor [corrected to Lin, E].

PMID:
19139433
[PubMed - indexed for MEDLINE]
Free Article
8.

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.

Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA.

Clin Cancer Res. 2008 Dec 1;14(23):7878-83. doi: 10.1158/1078-0432.CCR-08-0141.

PMID:
19047117
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

PMID:
18946061
[PubMed - indexed for MEDLINE]
Free Article
10.

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS; National Cancer Institute of Canada Clinical Trials Group Study BR.21.

J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14.

PMID:
18626007
[PubMed - indexed for MEDLINE]
Free Article
11.

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE.

N Engl J Med. 2007 Dec 27;357(26):2666-76.

PMID:
18160686
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A.

J Clin Oncol. 2007 Oct 20;25(30):4743-50. Epub 2007 Oct 1.

PMID:
17909199
[PubMed - indexed for MEDLINE]
Free Article
13.

Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma.

Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mössner J, Hauss J, Witzigmann H.

Eur J Surg Oncol. 2007 Oct;33(8):1025-9. Epub 2007 Apr 2.

PMID:
17400419
[PubMed - indexed for MEDLINE]
14.

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.

Eckel F, Schmid RM.

Br J Cancer. 2007 Mar 26;96(6):896-902. Epub 2007 Feb 27.

PMID:
17325704
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.

PMID:
17167137
[PubMed - indexed for MEDLINE]
Free Article
16.

Phase II study of erlotinib in patients with advanced biliary cancer.

Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C.

J Clin Oncol. 2006 Jul 1;24(19):3069-74.

PMID:
16809731
[PubMed - indexed for MEDLINE]
Free Article
17.

The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma.

Park BK, Paik YH, Park JY, Park KH, Bang S, Park SW, Chung JB, Park YN, Song SY.

Am J Clin Oncol. 2006 Apr;29(2):138-42.

PMID:
16601431
[PubMed - indexed for MEDLINE]
18.

Gallbladder cancer, a different disease that needs individual trials.

Gallardo J, Rubio B, Villanueva L, Barajas O.

J Clin Oncol. 2005 Oct 20;23(30):7753-4; author reply 7754-5. No abstract available.

PMID:
16234545
[PubMed - indexed for MEDLINE]
Free Article
19.

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ.

J Clin Oncol. 2005 Apr 1;23(10):2332-8.

PMID:
15800324
[PubMed - indexed for MEDLINE]
Free Article
20.

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.

Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A.

J Clin Oncol. 2005 Apr 10;23(11):2544-55. Epub 2005 Mar 7.

PMID:
15753462
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk